The effect of ethylene glycol monomethyl ether (EGME) and ethylene glycol monoethyl ether (EGEE) on cell-mediated immunity was evaluated by an allograft rejection assay. Allogeneic B6C3F1 (C57BL/6 x C3H) mice were given oral doses of 600, 1200, or 2400 mg/kg/administration of EGEE or 300, 600, 1200 mg/kg/administration of EGME on days -12 through -8 or cyclophosphamide (Cy) at 180 mg/kg by the IP route on day -1. Untreated controls were given oral doses of water on days -12 through -8 and -5 through -1. On day 0, the mice were challenged with 1 x 102, 3 x 103, and 1 x 105 or 3 x 106 L1210 cells by the IP route.
Introduction
In recent years, routine methods, based primarily on animal death and/or histopathological changes, have evolved to assess the toxicity and/or carcinogenicity of environmental pollutants. These approaches have aided in the identification of certain highly toxic environmental contaminants with acute effects (1) . The development of assays and/or batteries of techniques to determine the effects of these agents on more subtle cell functions has not evolved as rapidly, and indeed in many instances could proceed only after assays were developed to determine the mechanism(s) of cellular functions, differentiation, and interactions.
Attempts to apply assays of immune function to assess the effects of selected environmental pollutants on this key biological system have demonstrated the immunosuppressive effects ofheavy metals (2), polychlorinated biphenyls (3) , pesticides (4) , fossil fuel combustion products, polycyclic aromatic hydrocarbons, to mention a few, and in selected studies the mechanism(s) of these effects have been further clarified (1) . These types of studies coupled with the fact that accurate and sensitive assays of immune function have been (and continue to be) developed clearly indicate that immunotoxicology can and should be further developed and applied.
A variety of toxicological effects have been observed with ethylene glycol monomethyl ether (EGME) and ethylene glycol monoethyl ether (EGEE) including testicular atrophy (5), adverse reproductive effects (6, 7) , leukopenia (8) , and thymic atrophy (9) . Although no mechanistic explanations have been suggested as a common thread to explain these diverse observations, a simplistic hypothesis is that there may be direct cytotoxic effect on some rapidly growing tissues. Considering the contention of Trosko et al. (10) that interruption of intercellular communication may play a similar role in teratogenesis as well as tumor promotion and that various glycol ethers have been demonstrated to block gap junction-mediated intercellular communication (11), the glycol ethers were judged to be likely candidates for tumor promoting effects. In addition the observations of thymic atrophy in mice and rats also suggested the possibility of increased risk of tumor development through a decrease in thymus dependent cellular immunity. We chose to assess the effects of these chemicals on the immune system using an allogeneic tumor challenge model (12) . In this model, mice which are allogeneic in relation to the leukemic cell tumor used will not die when challenged unless they have been immunosuppressed, while in syngeneic mice the tumor will grow and kill the animals unless there is a direct cytotoxic effect as a result of chemical treatment on the tumor cells.
Materials and Methods
The test compounds, ethylene glycol monoethyl ether (CAS No. 110-80-5) and ethylene glycol monomethyl ether (CAS No. 109-86-4) were purchased from Aldrich (lot Nos. 0914EH and 3623ME, respectively). Commercially available cyclophosphamide (Mead Johnson) was used as a positive control, and distilled water was used as the negative control compound and for the dilution vehicle.
The mouse lymphoid leukemia L1210 was utilized in this study. Obtained originally from the National Cancer Institute (NCI), this ascitic tumor is propagated serially by intraperitoneal (IP) implantation in DBA/2 inbred mice (13) .
Female hybrid mice, B6C3F1 (C57BL/6 female x C3H male) and CD2F1 (BALB/c female x DBA/2 male) were purchased from the Animal Genetics and Production Branch, NCI. The mice were 5 to 6 weeks old and weighed 17 to 21 g. The mice were maintained in conformity with the standard guidelines (14) . They were housed in plastic cages (four to five mice per cage) with hardwood chip bedding and provided with dry pelleted mouse feed and water ad libitum. All mice were quarantined for 1 week prior to randomization. The mice were regularly inspected for gross signs of pathogenic conditions and injury.
The allogeneic mice were randomized four to a cage after the quarantine period. The cages were further randomized prior to assigning to a treatment group. Each treatment group consisted of two cages or a total of six to eight animals. Each animal in a cage was ear-marked for individual identification. The syngeneic mice were randomized immediately before tumor challenge.
L1210 ascitic fluid was harvested aseptically from healthy donor mice and placed in a sterile glass container on ice. A cell count was made using a hemocytometer, and the stock fluid was diluted in Hank's balanced salt solution to the desired cell concentration. The number of cells implanted intraperitoneally (3 x 106, 1 x 105, 3 x 10 , or 1 x 10 per mouse) was contained in 0.2 mL cell suspension.
Group body weights were taken once a week during the experimental period. Survival, general health conditions, and other clinical observations were recorded daily. Necropsies were performed to record the presence of leukemic ascites, splenomegaly, and hepatomegaly. Smears were made from retro-orbital sinus blood from each animal on the last day of dosing and on the day of death (or at 43 days post-tumor implantation for the allogeneic mice.) These smears were stained with Giemsa and differential cell counts were made.
The chemicals were prepared in appropriate concentrations and were administered to mice perorally in a volume of 0.01 mL/g body weight. The allogeneic B6C3F1 mice were treated daily from day -12 to day -8 and from day -5 to day -1. Day 0 was the tumor implantation day for both strains of mice. Cyclophosphamide at a dose of 180 mg/kg was injected intraperitoneally on day -1. The syngeneic CD2F1 mice were treated daily on days 1 to 5 and days 8 to 12. There was no cyclophosphamide-treated group in the syngeneic mice. The negative control group for each strain was given distilled water on the days corresponding to the chemical treatment days.
Results
The survival and weight results for the experiment are presented in Table 1 Necropsy of syngeneic mice showed hemorrhagic ascites and splenomegaly. Liver, lungs, and kidneys were normal in gross appearance for most animals. Groups which received the top two doses of the EGME compound, each had one mouse with no visible ascites and two each with a small quantity of ascites.
With the allogeneic mice, all animals died at the 3 x 106 challenge level in the cyclophosphamide-treated group and the water-treated controls (Tables 2 and 3 ). These groups differed significantly (p < 0.0001) from the 3 x 106 challenge groups treated with EGME (Table  2) or with the EGEE (Table 3) (Table 3 ).
All surviving allogeneic mice were sacrificed on day 43 for necropsy and blood smears. No mice showed any ascites and only 4 (6%) showed splenomegaly. Of the 67 mice treated with the EGEE that survived, 5 (7%) had enlarged gallbladders, while of the 79 mice treated with the EGME compound that survived, 46 (58%) had enlarged gallbladders. No surviving animals that received cyclophosphamide or water had enlarged gallbladders.
The data from the blood counts is seen in Tables 4 to  6 . In general, the morphology of the 'leukemic cells" appeared as atypical, vaculoized mononuclear cells with characteristic red granules. Syngeneic mice died with evidence of monocytosis which is presumed to be indicative of monocytic leukemia (Table 4) . Most of these treated animals were sacrificed and bled on day 43 after tumor challenge. A few mice treated with EGME Table 5 . Incidence of monocytic leukemia by differential cell count in allogeneic mice treated with EGME.a tSignificantly different from pretumor challenge (p < 0.00001). where the cyclophosphamide treated groups will die, but the water-treated controls will not (1 x 106 and 5 x 105). Further, higher doses of the compounds that would produce pronounced toxic effects (e.g., death, weight loss, bone marrow toxicity), as well as additional assays to assess immune competence, should be included.
Since these glycol ethers exhibit relatively low toxicity in organ systems other than the reproductive tract, are readily absorbed by various routes of administration, and appear to decrease background gross pathology, there may be enough evidence to warrant testing of these chemicals as potential therapeutic agents.
